Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Materials Select Sector SPDR Fund — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B), while Materials Select Sector SPDR Fund trades at $53.25. Which is the better fit depends on your goals.
| VRTX | XLB | |
|---|---|---|
Market Cap | $132.79B | — |
Sector | Health | — |
52-Week High | $529.65 | $53.62 |
52-Week Low | $376.62 | $42.23 |
Enterprise Value | $126.92B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
XLB trades at $52.86, up 1.32% today, with a bullish technical signal from moving averages and neutral oscillators. The materials sector benefits from AI infrastructure demand and strong Q2 earnings momentum, as noted by Zacks Investment Research on August 6, 2026. A dividend of $0.19 is scheduled for June 2026, while recent news highlights sector resilience amid geopolitical shifts.
Outlook is positive due to cyclical recovery and AI-driven demand, but risks include pricing pressures and economic sensitivity. Analysts see limited near-term upside after recent gains, with a hold rating common. Institutional interest remains strong, supporting stability amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
